Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has announced that its Board of Directors will convene on October 29, 2026. The primary agenda items include the consideration and approval of the Un-audited Consolidated and Standalone Financial Results for the quarter and half-year ended September 30, 2026. Additionally, the board will address other business matters. The company also reminded stakeholders that the trading window for securities, which was closed from October 1, 2026, will remain shut until 48 hours after the financial results are officially submitted to the stock exchanges, in accordance with the company's insider trading code.

Senores Pharmaceuticals Ltd announced that its Board of Directors has re-appointed Mr. Swapnil Jatinbhai Shah as the Managing Director and Mr. Chetan Bipinchandra Shah as the Whole-time Director. Both appointments are for a period of three consecutive years, effective from October 15, 2026, and November 10, 2026, respectively. These re-appointments are subject to shareholder approval via a postal ballot process. Mr. Shah brings over 15 years of experience in the pharmaceutical sector and holds an MBA from Hofstra University. The board meeting took place on October 13, 2026.

Senores Pharmaceuticals Ltd announced that its Board of Directors, in a meeting held on October 13, 2026, approved the re-appointment of Mr. Swapnil Jatinbhai Shah as the Managing Director for a period of three years, effective October 15, 2026. This re-appointment is subject to shareholder approval via a postal ballot. The Board also approved the re-appointment of Mr. Chetan Bipinchandra Shah as Whole Time Director for a period of three years, effective November 10, 2026, also subject to shareholder approval. Mr. Swapnil Jatinbhai Shah has over 15 years of experience in the pharmaceutical sector and is a promoter of the company.

Senores Pharmaceuticals Ltd has announced the closure of its trading window for directors, promoters, designated persons, and their immediate relatives. This closure is in compliance with SEBI PIT Regulations and the company's code of conduct for preventing insider trading. The window will be shut from October 01, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter and half-year ending September 30, 2026. All concerned individuals are advised against trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

Senores Pharmaceuticals Ltd has responded to a stock exchange query regarding unusual volume movements in its scrip. The company stated that it is in compliance with SEBI (LODR) Regulations and has promptly informed the exchanges of all material information. Senores Pharmaceuticals confirmed that there is no undisclosed price-sensitive information or any impending announcement or corporate action that needs to be disclosed at this time. They assured continued compliance with disclosure regulations.

Senores Pharmaceuticals Ltd announced that its subsidiary, Apnar Pharma Private Limited, located in Vadodara, has successfully completed its USFDA inspection. The inspection took place from September 7-11, 2026. Notably, there were no GMP-related observations, with only one minor procedural observation noted. Apnar Pharma will submit its response within the stipulated timeframe. This successful inspection is a positive development for the subsidiary's manufacturing capabilities and regulatory compliance.

Senores Pharmaceuticals Ltd has submitted a corrigendum to its Annual Report for the financial year 2025-26. This corrigendum addresses inadvertent typographical errors identified in the Narrative and Director's Report sections. The company assures that these corrections do not alter the substance or meaning of the disclosures. The revised report, incorporating these changes, will be available on the BSE, NSE, and the company's website. This corrigendum is being sent to shareholders to inform them of the minor amendments.

Senores Pharmaceuticals Ltd has submitted its Annual Report for the financial year 2025-26, along with the notice for its Ninth Annual General Meeting (AGM). The AGM is scheduled for September 25, 2026, at 11:30 AM IST, to be conducted via Video Conferencing. The report includes the Business Responsibility and Sustainability Report. Members will receive the report electronically. Key dates for e-voting are September 18-24, 2026. The annual report details the company's corporate overview, management message, business segments, financials, and ESG commitment, highlighting a 'Positioned for the Next Leap' strategy focusing on organic growth and strategic acquisitions.

Senores Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI Listing Regulations. The report, also available on the company's website, details the company's operations, product/service offerings, and market presence. Senores Pharma, a B2B pharmaceutical developer and manufacturer, reported a turnover of INR 10,609 lakhs and a net worth of INR 74,990 lakhs for the fiscal year. Exports contributed 43.95% to the total turnover. The company operates on a standalone basis for its disclosures and has a grievance redressal mechanism in place for stakeholders.

Senores Pharmaceuticals Ltd has submitted the notice for its 9th Annual General Meeting (AGM) and the Annual Report for the financial year 2025-26. The AGM is scheduled for Friday, September 25, 2026, at 11:30 AM IST, to be conducted via Video Conferencing/Other Audio-Visual Means. The report includes the Business Responsibility and Sustainability Report. The cut-off date for determining e-voting eligibility is September 18, 2026, with remote e-voting open from September 22 to September 24, 2026. The Annual Report details the company's corporate overview, management message, business segments, financials, and ESG commitments, highlighting a strong growth trajectory and expanded market presence.